Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration

Micro-Abstract In patients with chronic lymphocytic leukemia (CLL), those who received chemoimmunotherapy had a survival advantage compared with those who were treated with purine analogues only. This beneficial effect was observed regardless of the phase of the disease at which treatment was given.

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2014-02, Vol.14 (1), p.73-79
Main Authors: Delgado, Julio, Ghita, Gabriela, Baumann, Tycho, Santacruz, Rodrigo, Dlouhy, Ivan, Aymerich, Marta, Rozman, Maria, Creus, Natalia, Pereira, Arturo, Montserrat, Emili
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Anti-CD20
Antibodies, Monoclonal, Murine-Derived - administration & dosage
Antineoplastic Agents - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
CLL
Female
Hematology, Oncology and Palliative Medicine
Humans
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell - mortality
Male
Middle Aged
Purine analogues
Purines - agonists
Rituximab
Treatment
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract In patients with chronic lymphocytic leukemia (CLL), those who received chemoimmunotherapy had a survival advantage compared with those who were treated with purine analogues only. This beneficial effect was observed regardless of the phase of the disease at which treatment was given.
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2013.08.003